IP Verse

Chimeric Antigen Receptors (Cars) Targeting Hematologic Malignancies, Compositions And Methods Of Use Thereof - EP3261651

The patent EP3261651 was granted to Chen on May 4, 2022. The application was originally filed on Feb 26, 2016 under application number EP16756524A. The patent is currently recorded with a legal status of "Revoked".

EP3261651

CHEN
Application Number
EP16756524A
Filing Date
Feb 26, 2016
Status
Revoked
Feb 21, 2025
Grant Date
May 4, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEFeb 3, 2023CARPMAELS & RANSFORDADMISSIBLE
MARGARET DIXONFeb 3, 2023MEWBURN ELLISADMISSIBLE
PATENT BOUTIQUEFeb 3, 2023PATENT BOUTIQUEADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONFR901228
DESCRIPTIONUS5350674
DESCRIPTIONUS5585362
DESCRIPTIONUS6326193
DESCRIPTIONWO0129058
DESCRIPTIONWO0196584
DESCRIPTIONWO2013126712
INTERNATIONAL-SEARCH-REPORTUS2002009449
INTERNATIONAL-SEARCH-REPORTUS2005277587
INTERNATIONAL-SEARCH-REPORTUS2008254027
INTERNATIONAL-SEARCH-REPORTUS2009325188
INTERNATIONAL-SEARCH-REPORTUS2012058082
INTERNATIONAL-SEARCH-REPORTUS2012134970
INTERNATIONAL-SEARCH-REPORTUS2013058936
INTERNATIONAL-SEARCH-REPORTUS2013259876
INTERNATIONAL-SEARCH-REPORTUS2013287748
OPPOSITIONUS201562121842P
OPPOSITIONWO2013126712
OPPOSITIONWO2015121454
OPPOSITIONWO2016126213
SEARCHWO2013126712

Non-Patent Literature (NPL) Citations (34) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- H Rabinowich ET AL, "Expression and function of CD7 molecule on human natural killer cells", The Journal of Immunology, US, (19940115), vol. 152, no. 2, ISSN 0022-1767, pages 517 - 526, XP055736910-
EXAMINATION- Imboden John B ET AL, "Stimulation of CDS Enhances Signal Transduction by the T Cell Antigen Receptor", (19900101), pages 130 - 134, URL: https://dm5migu4zj3pb.cloudfront.net/manuscripts/114000/114402/cache/114402.1-20201218131503-covered-e0fd13ba177f913fd3156f593ead4cfd.pdf, (20211008), XP055849501-
EXAMINATION- Me Mcnerney ET AL, "The CO2 family of natural killer cell receptors. -PubMed -NCBI The CD2 family of natural killer cell receptors", (20060101), page 1, URL: https://pubmed.ncbi.nlm.nih.gov/16323413/, (20211008), XP055849504-
EXAMINATION- Moeller Maria ET AL, "Sustained Antigen-Specific Antitumor Recall Response Mediated by Gene-Modified co4+ T Helper-1 and cos+ T Cells", (20070101), pages 11428 - 11437, URL: https://cancerres.aacrjournals.org/content/67/23/11428.long, (20211008), XP055849508-
EXAMINATION- RABINOWICH H ET AL, "Signaling via CD7 molecules on human NK cells: Induction of tyrosine phosphorylation and beta-1 integrin-mediated adhesion to fibronectin", THE JOURNAL OF IMMUNOLOGY, WILLIAMS & WILKINS CO, US, (19940101), vol. 153, no. 8, ISSN 0022-1767, pages 3504 - 3513, XP002156206-
EXAMINATION- LIU LISA L. ET AL, "Critical Role of CD2 Co-stimulation in Adaptive Natural Killer Cell Responses Revealed in NKG2C-Deficient Humans", CELL REPORTS, US, (20160501), vol. 15, no. 5, doi:10.1016/j.celrep.2016.04.005, ISSN 2211-1247, pages 1088 - 1099, XP055849502
EXAMINATION- LEWIS R E ET AL, "The immunophenotype of pre-TALL/LBL revisited", EXPERIMENTAL AND MOLECULAR PATHOLOGY, ACADEMIC PRESS, US, vol. 81, no. 2, doi:10.1016/J.YEXMP.2006.06.006, ISSN 0014-4800, (20061001), pages 162 - 165, (20061001), XP024944870
EXAMINATION- D Sommermeyer ET AL, "Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo", Leukemia, London, (20150915), vol. 30, no. 2, doi:10.1038/leu.2015.247, ISSN 0887-6924, pages 1 - 20, XP055569635
EXAMINATION- MOELLER M ET AL, "Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (20051101), vol. 106, no. 9, doi:10.1182/BLOOD-2004-12-4906, ISSN 0006-4971, pages 2995 - 3003, XP003022406
EXAMINATION- Litzow Mark R. ET AL, "Abstract", US, vol. 126, no. 7, doi:10.1182/blood-2014-10-551895, ISSN 0006-4971, (20150813), pages 833 - 841, Blood, URL: http://ashpublications.org/blood/article-pdf/126/7/833/1390786/833.pdf, XP055790717
EXAMINATION- M. Mamonkin ET AL, "A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies", Blood, US, (20150820), vol. 126, no. 8, doi:10.1182/blood-2015-02-629527, ISSN 0006-4971, pages 983 - 992, XP055325148
OPPOSITION- Choi Mira et al, "A Case of Primary Cutaneous CD4 Positive Small/medium T Cell Lymphoma", Ann Dermatol, (20110101), vol. 23, no. 1, pages 76 - 80, XP093026832-
OPPOSITION- Frankel Arthur E. et al, "Therapy of Patients with T-Cell Lymphomas and Leukemias Using an Anti-CD7 Monoclonal Antibody-Ricin A Chain Immunotoxin", Leukemia and Lymphoma, (19970101), vol. 26, pages 287 - 298, XP093028145-
OPPOSITION- Hishima Tsunekazu et al, "Short Communication CD5 Expression in Thymic Carcinoma", American Journal of Pathology, (19940801), vol. 145, no. 2, pages 268 - 275, XP093026797-
OPPOSITION- Hussong Jerry W. et al, "Protocol for the Examination of Specimens From Patients With Non-Hodgkin Lymphoma/Lymphoid Neoplasms. Version 3.2.0.1", College of American Pathologists, (20131001), pages 1 - 15, XP093026795-
OPPOSITION- Kapp Katja, "Post-Targeting Functions of Signal Peptides", Protein Transport into the Endoplasmic Reticulum, (20090101), pages 1 - 16, XP093026787-
OPPOSITION- Lemaistre C F, et al, "Phase I Trial of H65-RTA Immunoconjugate in Patients With Cutaneous T-Cell Lymphoma", Blood, (19910901), vol. 78, no. 5, pages 1173 - 1182, XP093028150-
OPPOSITION- Li Shiyong, Et Al, "Flow Cytometry in the Differential Diagnosis of Lymphocyte-Rich Thymoma From Precursor T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma", Am J Clin Pathol, (20040101), vol. 121, pages 268 - 274, XP093026793-
OPPOSITION- Vivante F. et al, "The CD4 molecule belongs to the phenotypic repertoire of most cases of acute myeloid leukemia", Leukemia, (19920101), vol. 6, no. 12, pages 1257 - 1262, XP093026450-
OPPOSITION- LEWIS et al., "The immunophenotype of pre-TALL/LBL revisited", Experimental and Molecular Pathology, (20060000), vol. 81, no. 2, doi:10.1016/j.yexmp.2006.06.006, pages 162 - 165, XP024944870
OPPOSITION- MORRIS et al., "Antibody-based therapy of leukaemia", Expert Rev Mol Med, (20090000), vol. 11, doi:10.1017/S1462399409001215, page e29, XP009142309
OPPOSITION- Pinz K. et al, "Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells", Leukemia, Nature Publishing Group UK, London, London, (20160301), vol. 30, no. 3, doi:10.1038/leu.2015.311, ISSN 0887-6924, pages 701 - 707, XP037323994
OPPOSITION- Miwa H. et al, "Biphasic expression of CD4 in acute myelocytic leukemia (AML) cells: AML of monocyte origin and hematopoietic precursor cell origin", Leukemia, Nature Publishing Group UK, London, London, (19980101), vol. 12, no. 1, doi:10.1038/sj.leu.2400877, ISSN 0887-6924, pages 44 - 51, XP037783563
OPPOSITION- DOTTI G. ET AL., "Design and development of therapies using chimeric antigen receptor-expressing T cells", IMMUNOL. REV., (20131213), vol. 257, no. 1, doi:10.1111/imr.12131, pages 107 - 126, XP002791515
OPPOSITION- M. Sadelain et al, "The Basic Principles of Chimeric Antigen Receptor Design", Cancer Discovery, (20130401), vol. 3, no. 4, doi:10.1158/2159-8290.CD-12-0548, ISSN 21598274, pages 388 - 398, XP055133523
OPPOSITION- B. Jena et al, "Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor", Blood, (20100819), vol. 116, no. 7, doi:10.1182/blood-2010-01-043737, ISSN 00064971, pages 1035 - 1044, XP055021403
OPPOSITION- MAMONKIN et al., "A T- cell -directed chimeric antigen receptor for the selective treatment of T- cell malignancies", Blood, (20150000), vol. 126, no. 8, doi:10.1182/blood-2015-02-629527, pages 983 - 992, XP055325148
OPPOSITION- M. Mamonkin et al, "A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies", Blood, American Society of Hematology, US, US , (20150820), vol. 126, no. 8, doi:10.1182/blood-2015-02-629527, ISSN 0006-4971, pages 983 - 992, XP055325148
OPPOSITION- M. Mamonkin, Et Al., "A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies", Blood, American Society of Hematology, US, US , (20150820), vol. 126, no. 8, doi:10.1182/blood-2015-02-629527, ISSN 0006-4971, pages 983 - 992, XP055325148
OPPOSITION- Posey Avery D. et al, "Glycopeptide-Specific Chimeric Antigen Receptor Targeting of T Cell Leukemia", Blood, American Society of Hematology, US, US , (20141114), vol. 124, no. 21, doi:10.1182/blood.V124.21.4803.4803, ISSN 0006-4971, page 4803, XP086739986
OPPOSITION- Jennifer R. Brown et al, "Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward", American Society of Clinical Oncology Educational Book, (20140101), vol. 34, doi:10.14694/EdBook_AM.2014.34.e317, ISSN 15488748, pages e317 - e325, XP055201368
OPPOSITION- Katayoun Rezvani, Rayne H. Rouce, "The Application of Natural Killer Cell Immunotherapy for the Treatment of Cancer", Frontiers in Immunology, vol. 6, doi:10.3389/fimmu.2015.00578, XP055496595
OPPOSITION- Wolfgang Glienke et al, "Advantages and applications of CAR-expressing natural killer cells", Frontiers in Pharmacology, vol. 6, doi:10.3389/fphar.2015.00021, XP055405884
SEARCH- JENNIFER R. BROWN ET AL, "Novel Treatments for Chronic Lymphocytic Leukemia and Moving Forward", AMERICAN SOCIETY OF CLINICAL ONCOLOGY EDUCATIONAL BOOK, (2014), vol. 34, doi:10.14694/EdBook_AM.2014.34.e317, ISSN 1548-8748, pages e317 - e325, XP055201368 [I] 1-14 * See � "THE USE OF CHIMERIC ANTIGEN RECEPTORMODIFIED T CELLS TO TREAT CLL" *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents